549
Views
14
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the treatment of neuromyelitis optica

, , &
Pages 285-297 | Received 15 May 2020, Accepted 28 Jul 2020, Published online: 25 Aug 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Patrick Schindler, Orhan Aktas, Marius Ringelstein, Brigitte Wildemann, Sven Jarius, Friedemann Paul & Klemens Ruprecht. (2023) Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Review of Clinical Immunology 19:1, pages 71-91.
Read now

Articles from other publishers (13)

Edgar Carnero Contentti, Pablo A Lopez, Verónica Tkachuk, Carlos Vrech, María A Zarate, Jorge Correale, Norma Deri, Geraldine Luetic, Mariano Marrodan, Fátima Pagani Cassara, Darío Tavolini, María Célica Ysrraelit, María E Balbuena, Javier Hryb, Edson Chiganer, Felisa Leguizamon, Eduardo Knorre, Gisela Zanga, Claudia Pestchanker, Andrés Barboza, Débora Nadur, Edgardo Cristiano, Liliana Patrucco, Ricardo Alonso, Marina Alonso Serena, Friedemann Paul & Juan Ignacio Rojas. (2023) Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting. Multiple Sclerosis Journal.
Crossref
Darius Mewes, Joseph Kuchling, Patrick Schindler, Ahmed Abdelrahim Ahmed Khalil, Sven Jarius, Friedemann Paul & Claudia Chien. (2022) Diagnostik der Neuromyelitis-optica-Spektrum-Erkrankung (NMOSD) und der MOG-Antikörper-assoziierten Erkrankung (MOGAD). Klinische Monatsblätter für Augenheilkunde 239:11, pages 1315-1324.
Crossref
Jie Ding, Xianguo Jiang, Yu Cai, Shuting Pan, Ye Deng, Meichun Gao, Yan Lin, Nan Zhao, Ze Wang, Haojun Yu, Huiying Qiu, Yuyan Jin, Jiahui Xue, Quan Guo, Liping Ni, Ying Zhang, Yong Hao & Yangtai Guan. (2022) Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study. CNS Neuroscience & Therapeutics 28:10, pages 1613-1623.
Crossref
Tobias Ruck, Falk Nimmerjahn, Heinz Wiendl & Jan D Lünemann. (2022) Next-generation antibody-based therapies in neurology. Brain 145:4, pages 1229-1241.
Crossref
Jia Ma, Haihua Yu, Hao Wang, Xinghu Zhang & Kai Feng. (2022) Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. Journal of Neuroimmunology 363, pages 577790.
Crossref
Hye Lim Lee, Su-Hyun Kim, Jin Myoung Seok, Byung Jo Kim, Ho Jin Kim & Byoung Joon Kim. (2022) Results of a Survey on Diagnostic Procedures and Treatment Choices for Neuromyelitis Optica Spectrum Disorder in Korea: Beyond the Context of Current Clinical Guidelines. Journal of Clinical Neurology 18:2, pages 207.
Crossref
Tobias Zrzavy, Fritz Leutmezer, Paulus Rommer, Gabriel Bsteh, Barbara Kornek, Thomas Berger, Daniela Prayer, Majda Thurnher & Lukas Haider. (2022) Imaging features to distinguish AQP4-positive NMOSD and MS at disease onset: A retrospective analysis in a single-center cohort. European Journal of Radiology 146, pages 110063.
Crossref
Susanna Asseyer, Hiroki Masuda, Masahiro Mori, Judith Bellmann-Strobl, Klemens Ruprecht, Nadja Siebert, Graham Cooper, Claudia Chien, Ankelien Duchow, Jana Schließeit, Jia Liu, Kazuo Sugimoto, Akiyuki Uzawa, Ryohei Ohtani, Friedemann Paul, Alexander U Brandt, *Satoshi Kuwabara & *Hanna G Zimmermann. (2021) AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical 7:2, pages 205521732110068.
Crossref
Ilya Ayzenberg & Ingo Kleiter. (2021) Therapie antikörpervermittelter EnzephalomyelitidenTreatment of antibody-mediated encephalomyelitis. Der Nervenarzt 92:4, pages 334-348.
Crossref
Jie Ding, Yu Cai, Ye Deng, Xianguo Jiang, Meichun Gao, Yan Lin, Nan Zhao, Ze Wang, Haojun Yu, Wenwen Lv, Ying Zhang, Yong Hao & Yangtai Guan. (2021) Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study. Frontiers in Neurology 12.
Crossref
Oliver Schmetzer, Elisa Lakin, Ben Roediger, Ankelien Duchow, Susanna Asseyer, Friedemann Paul & Nadja Siebert. (2021) Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology 12.
Crossref
Ankelien Duchow & Judith Bellmann-Strobl. (2021) Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative Disease Management 11:1, pages 49-59.
Crossref
Staley A. Brod. (2020) Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Multiple Sclerosis and Related Disorders 46, pages 102538.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.